Activity of brentuximab vedotin in AIDS-related primary effusion lymphoma.

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

Who cites it

6 citing papers in PubMed.

1. Promising immunotherapeutic approaches for primary effusion lymphoma.Exploration of targeted anti-tumor therapy · 2024
   Review
2. Immunotherapy for KSHV-associated diseases.Current opinion in virology · 2022
   Review
3. KSHV/HHV8-mediated hematologic diseases.Blood · 2022
   Review
4. Use of Brentuximab Vedotin in a Non-HIV Patient with Primary Effusion Lymphoma.European journal of case reports in internal medicine · 2021
   Article
5. [Primary effusion lymphoma in a HIV-negative patient: case report and literatures review].Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi · 2020
   Review
6. T Cell Primary Effusion Lymphoma in an HIV-Negative Man with Liver Cirrhosis.The American journal of case reports · 2020
   Article

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

Authors and funding

3 authors.

Funding

No grant is acknowledged in the PubMed record.

Abstract

PubMed holds no abstract for this paper.

Indexed as